EBMT 2019 | T-cell depleted haploidentical SCT followed by ATIR101 vs. T-cell replete HSCT plus chemo

Denis-Claude Roy

Denis-Claude Roy, MD, FRCPC, from the University of Montreal, Montreal, Canada, discusses a Phase III trial of haploidentical transplant with a T-cell depleted stem cell graft repleted with anti-leukemia and anti-viral allogeneic T-cells vs. a T-cell replete transplant followed by cyclophosphamide (NCT02999854). This interview took place at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video